CA3107192C - Constructions d'anticorps pour cldn18.2 et cd3 - Google Patents

Constructions d'anticorps pour cldn18.2 et cd3

Info

Publication number
CA3107192C
CA3107192C CA3107192A CA3107192A CA3107192C CA 3107192 C CA3107192 C CA 3107192C CA 3107192 A CA3107192 A CA 3107192A CA 3107192 A CA3107192 A CA 3107192A CA 3107192 C CA3107192 C CA 3107192C
Authority
CA
Canada
Prior art keywords
seq
depicted
antibody construct
cdr
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3107192A
Other languages
English (en)
Other versions
CA3107192A1 (fr
Inventor
Christoph Dahlhoff
Claudia Bluemel
Johannes Brozy
Tobias Raum
Elisabeth Nahrwold
Tara Arvedson
Irwin Chen
Sandra Ross
Julie Bailis
Original Assignee
Amgen Research Munich GmbH
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Research Munich GmbH, Amgen Inc filed Critical Amgen Research Munich GmbH
Priority claimed from PCT/EP2019/070886 external-priority patent/WO2020025792A1/fr
Publication of CA3107192A1 publication Critical patent/CA3107192A1/fr
Application granted granted Critical
Publication of CA3107192C publication Critical patent/CA3107192C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente invention concerne une construction d'anticorps comprenant un domaine qui se lie à la claudine 18.2 (CLDN18.2) et un autre domaine qui se lie à CD3. De plus, l'invention concerne un polynucléotide codant pour la construction d'anticorps, un vecteur comprenant ledit polynucléotide et une cellule hôte transformée ou transfectée avec ledit polynucléotide ou vecteur. En outre, l'invention concerne un procédé de production de la construction d'anticorps de l'invention, une utilisation médicale de ladite construction d'anticorps et un kit comprenant ladite construction d'anticorps.
CA3107192A 2018-08-03 2019-08-02 Constructions d'anticorps pour cldn18.2 et cd3 Active CA3107192C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862714366P 2018-08-03 2018-08-03
US62/714,366 2018-08-03
PCT/EP2019/070886 WO2020025792A1 (fr) 2018-08-03 2019-08-02 Constructions d'anticorps pour cldn18.2 et cd3

Publications (2)

Publication Number Publication Date
CA3107192A1 CA3107192A1 (fr) 2020-02-06
CA3107192C true CA3107192C (fr) 2025-11-25

Family

ID=

Similar Documents

Publication Publication Date Title
US20240174745A1 (en) Antibody Constructs for CLDN18.2 and CD3
US12435139B2 (en) Antibody constructs for DLL3 and CD3
CA2982682A1 (fr) Constructions d'anticorps bispecifiques pour cdh3 et cd3
JP7837331B2 (ja) Ｃｌｄｎ６及びｃｄ３に選択的に結合するポリペプチド構築物
US20230093169A1 (en) Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
CA3107192C (fr) Constructions d'anticorps pour cldn18.2 et cd3
EA048433B1 (ru) Конструкции на основе антител для связывания cldn18.2 и cd3